Summary: Heart failure (HF) is a common and serious clinical problem arising from cardiovascular diseases as well as from metabolic disturbances, including diabetes mellitus type 2 (T2DM). Despite the continuous development of knowledge about the prevention and treatment of HF, it is still necessary to search for new therapeutic options to improve patients' prognosis. The results of large clinical trials evaluating the cardiovascular safety of type 2 sodium-glucose cotransporter (SGLT2) inhibitors have shown, besides hypoglycemic effect, additional benefits for patients with HF. The cardioprotective effect has also been observed in patients with HF without T2DM. The aim of this study is to summarize recent data on the safety and efficacy of SGLT2 inhibitor therapy in the HF patient population, regardless of impaired glucose metabolism.